Answers are grounded in this paper and cite their sources.
Low-grade systemic inflammation (LSSI) is a key factor in the onset and progression of type 2 diabetes mellitus (T2DM) and associated cardiovascular diseases (CVD). Indeed, inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and IL-6 are known to predict the development of T2DM and its complications. Overeating, unhealthy diet, physical inactivity, obesity, and aging are recognized triggers of LSSI that contribute to insulin resistance and participate in the pathogenesis of T2DM. After the development of T2DM, hyperglycemia, dyslipidemia, accumulation of senescent cells, stimulation of immune cells, changes in trained immunity, meta-inflammation, and renal dysfunction maintain LSSI and increase the risk of vascular pathology. However, the effect on inflammatory processes is not included in traditional T2DM treatment regimens. On the other hand, individual disease-modifying drugs, such as glucagon-like peptide type 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors, appear to reduce systemic inflammation and may prevent the development of T2DM and CVD when administered early. In addition, the effect of other anti-inflammatory drugs on SIDS in patients with T2DM is being studied. This literature review is devoted to the analysis of literature data on the role of SIDS in the development and progression of T2DM, CVD, as well as the role of anti-inflammatory and hypoglycemic drugs in the prevention of SIDS, T2DM (and/or its compensation).
No takes yet. Share an insight, caveat, or question.
Bulgakova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: